Validation of a Patient Reported Experience Measure (PREM) in Patients with Axial Spondyloarthropathies (AxSpA)

Clare Longton¹, Marco Massarotti² and Marwan Bukhari³, ¹Rheumatology, Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ²Rheumatology, Royal Lancaster Infirmary, University Hospital of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ³Royal Lancaster Infirmary, Lancaster, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: patient questionnaires and spondylarthropathy, Patient Satisfaction, Validity

Session Information

Date: Monday, November 14, 2016

Title: Quality Measures and Quality of Care - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Improving patient experience is important in all diseases, but most important in patients with chronic rheumatic diseases like the axial spondyloarthropathies (AxSpa). The Commissioning for Quality in Rheumatoid Arthritis (CQRA), a British multidisciplinary group of stakeholders, developed a PREM questionnaire to evaluate patient satisfaction in rheumatology. The questionnaire comprises 8 domains that have been evidenced as being most important to patients’ experiences of National Health Service (NHS) services. All questions were graded from very satisfied to very unsatisfied on a five point scale. This PREM was validated within Rheumatoid Arthritis and a variety of rheumatic conditions in a previous publication (Bosworth A et al. 2015). This has not yet been published and validated within a cohort of patients with AxSpa. Our aim was to determine the validity of the PREM questionnaire developed by the CQRA group in a single centre AxSpa clinic.

Methods: Cronbachs alpha was used to check internal consistency within groups of scores in each domain if it contained more than one question and whether it was reasonable to combine scores within groups into a numerical scale. Additionally for each question the percentage agreement with the overall assessment on the five point scale was calculated, in case of multiple questions per domain, the responses are shown as a range.

Results: 64 patients were included in the analysis (mean age 51.6 ± SD11.7; M 58/64, 87.5%). Duration of disease equated >10years in 71.9%. The Cronbach alpha co-efficients within the multi-question domains and their percentage agreement with the question on overall care are shown in the table below. Table. Result of Cronbach’s alpha analysis and their agreement with overall care

Domain	Number of questions	Alpha Within domain	%Agreement with overall care
Needs and preferences	5	0.71	0.75
Co-ordination of care	4	0.81	0.84
Information about care	4	0.88	0.87
Daily living	2	0.25	0.52
Emotional aspects	2	0.81	0.75
Family and friends	1	NA	0.34
Access to care	1	NA	0.61

Conclusion: The PREM has good construct validity and is a valid tool for measuring AxSpa patient experience. Some domains have higher agreement with overall patient experience. This could provide a useful future tool for measuring patient experience.

Disclosure: C. Longton, None; M. Massarotti, None; M. Bukhari, Merck, Roche, Mennarini, Amgen, Pfizer, Eli-Lilly, Sanofi-Aventis , Abbvie, 8.

To cite this abstract in AMA style:

Longton C, Massarotti M, Bukhari M. Validation of a Patient Reported Experience Measure (PREM) in Patients with Axial Spondyloarthropathies (AxSpA) [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/validation-of-a-patient-reported-experience-measure-prem-in-patients-with-axial-spondyloarthropathies-axspa/. Accessed .

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-a-patient-reported-experience-measure-prem-in-patients-with-axial-spondyloarthropathies-axspa/